MarketPulse

weight loss medications

9 articles
Investing.comInvesting.com··Nathan Reiff

Lilly's Double-Beat Widens GLP-1 Gap as Foundayo Pill Transforms Market

Eli Lilly beats Q1 earnings, raises $2B guidance, and wins FDA approval for Foundayo, the first unrestricted oral GLP-1, widening gap over Novo Nordisk.
LLYNVOFDA approvalweight loss medications
The Motley FoolThe Motley Fool··James Brumley

Viking Therapeutics Stock Could Double as GLP-1 Rival Advances Toward FDA Approval

Wall Street projects 170% upside for Viking Therapeutics' obesity drug candidate VK2735, citing superior weight loss and tolerability versus Novo Nordisk and Eli Lilly rivals.
LLYNVOVKTXFDA approvalPhase 3 trials
BenzingaBenzinga··Bamboo Works

Kailera's 63% IPO Surge Validates Chinese Pharma 'NewCo' Spinoff Strategy

Kailera Therapeutics surged 63% on Nasdaq debut as weight-loss drug spinoff from Hengrui Pharma, raising $625M and validating the 'NewCo' model for Chinese pharmaceutical companies.
LLYNVOGILDJHPCYKLRAIPOGLP-1 drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novo Nordisk's Subscription Model Could Unlock Massive Obesity Market Despite Lilly Competition

Novo Nordisk launches tiered subscription pricing for Wegovy to expand obesity drug access. Stock trades at attractive 11x forward earnings amid market penetration opportunity.
LLYNVOGLP-1 drugsweight loss medications
The Motley FoolThe Motley Fool··Geoffrey Seiler

Hims & Hers Surges 40% on Novo Nordisk Deal, But Valuation Concerns Linger

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.
NVOHIMSGLP-1 drugstelemedicine
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks; Analysts Eye Cheaper Alternatives

Eli Lilly trades at premium 44 P/E despite GLP-1 concentration risks. Novo Nordisk and Pfizer offer higher yields and lower valuations.
PFELLYNVOvaluationbiotech
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly Expands Obesity Drug Lead With Clinical Win and Product Innovation

Eli Lilly strengthens obesity drug dominance as competitor's treatment fails trials and Lilly launches new monthly-dose Zepbound pen, commanding 60% market share.
PFELLYNVOVKTXclinical trialsGLP-1 drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novo Nordisk's GLP-1 Dominance May Not Deliver Mega Returns

Novo Nordisk dominates the GLP-1 market with Ozempic and Wegovy, but faces stiff competition from Eli Lilly and disappointing trial results that may limit exceptional long-term returns.
LLYNVOdividend stockslong-term investing
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Intuitive Surgical Posts Double-Digit Growth Despite GLP-1 Drug Market Spotlight

Intuitive Surgical posts double-digit growth in 2025 with 12% installed base expansion and 18% surgery increase, unaffected by GLP-1 drug market competition.
LLYNVOISRGGLP-1 drugsgrowth stocks